Skip to content
PICO Portalanswers from OpenAlex

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

PaperCitations, authors & open-access status

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment is a paper indexed in PICO Portal from OpenAlex.

How many citations does Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment have?

PICO Portalcitation count

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment has 80 citations in the OpenAlex counts PICO Portal stores.

When was Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment published?

PICO Portalyear

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment has 2020 year in the PICO Portal index.

What is the open-access status of Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment?

PICO Portaloa status

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment has hybrid oa status in the PICO Portal index.

What is the DOI of Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment?

PICO Portaldoi

The DOI for Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment is on the source record.

What is the PMID of Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment?

PICO Portalpmid

The PMID for Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment is on the source record.

What is the OpenAlex record for Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment?

PICO Portalopenalex

The OpenAlex for Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial